Xeris Biopharma Tops Q4 EPS Estimates, Reports $85.8M Revenue
Xeris Biopharma reported Q4 2025 EPS of $0.06 versus estimates of $0.03 and revenue of $85.8 million slightly below projections. The company’s P/S ratio stands at 3.48, debt-to-equity at 2.76 and it issued optimistic financial guidance for 2026 highlighting growth potential.
1. Q4 2025 Financial Results
Xeris Biopharma delivered Q4 2025 EPS of $0.06 versus estimates of $0.03 and recorded $85.8 million in revenue, narrowly below consensus. Management highlighted strong operational execution and provided bullish guidance for 2026 revenue growth.
2. Valuation Metrics
At quarter-end, the company’s price-to-sales ratio stood at 3.48x and enterprise value-to-sales at 3.23x, signaling robust market sentiment. However, an enterprise value-to-operating cash flow multiple of 109.77x suggests cash flow generation remains an area for investor scrutiny.
3. Liquidity and Leverage
Xeris carried a debt-to-equity ratio of 2.76x at the close of Q4 and maintained a current ratio of 2.19x, indicating adequate short-term liquidity. While leverage is elevated, the strong current ratio provides a cushion for near-term obligations.